Does the media prefer VNT or EYPT?

In the previous week, Vontier had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for Vontier and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.96 beat Vontier's score of 0.81 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vontier 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MIR or EYPT?

In the previous week, Mirion Technologies had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 9 mentions for Mirion Technologies and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.96 beat Mirion Technologies' score of 0.73 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirion Technologies 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AEHR or EYPT?

In the previous week, Aehr Test Systems had 8 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 12 mentions for Aehr Test Systems and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.96 beat Aehr Test Systems' score of 0.83 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aehr Test Systems 5 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to EYPT or ALNT?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 4 articles in the media. Allient's average media sentiment score of 1.25 beat Eyepoint Pharmaceuticals' score of 0.96 indicating that Allient is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Allient 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Eyepoint Pharmaceuticals (EYPT) Competitors

$12.19 -0.28 (-2.25%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$12.34 +0.16 (+1.27%)

As of 07/24/2026 07:34 PM Eastern

Compare

EYPT vs. VNT, MIR, AEHR, ALMR, and ALNT

Should you buy Eyepoint Pharmaceuticals stock or one of its competitors? MarketBeat compares Eyepoint Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eyepoint Pharmaceuticals include Vontier (VNT), Mirion Technologies (MIR), Aehr Test Systems (AEHR), Alamar Biosciences (ALMR), and Allient (ALNT). These companies are all part of the "measuring and control equipment" industry.

How does Eyepoint Pharmaceuticals compare to Vontier?

Vontier (NYSE:VNT) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both measuring and control equipment companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

Vontier presently has a consensus target price of $41.89, suggesting a potential upside of 36.11%. Eyepoint Pharmaceuticals has a consensus target price of $43.75, suggesting a potential upside of 258.90%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Vontier.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vontier	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

95.8% of Vontier shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 1.1% of Vontier shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Vontier had 1 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 5 mentions for Vontier and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.96 beat Vontier's score of 0.81 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vontier	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vontier has a net margin of 13.37% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Vontier's return on equity of 37.88% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vontier	13.37%	37.88%	10.90%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Vontier has a beta of 1.16, meaning that its stock price is 16% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

Vontier has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Vontier, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vontier	$3.09B	1.40	$406.10M	$2.83	10.87
Eyepoint Pharmaceuticals	$7.61M	134.23	-$231.96M	-$3.50	N/A

Summary

Eyepoint Pharmaceuticals beats Vontier on 9 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Mirion Technologies?

Mirion Technologies (NYSE:MIR) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both measuring and control equipment companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Mirion Technologies currently has a consensus price target of $27.00, indicating a potential upside of 63.40%. Eyepoint Pharmaceuticals has a consensus price target of $43.75, indicating a potential upside of 258.90%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Mirion Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirion Technologies	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

78.5% of Mirion Technologies shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 6.3% of Mirion Technologies shares are owned by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Mirion Technologies had 5 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 9 mentions for Mirion Technologies and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.96 beat Mirion Technologies' score of 0.73 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirion Technologies	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirion Technologies has a net margin of 2.56% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Mirion Technologies' return on equity of 6.44% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirion Technologies	2.56%	6.44%	3.48%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Mirion Technologies has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

Mirion Technologies has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Mirion Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirion Technologies	$981M	4.22	$28.80M	$0.10	165.24
Eyepoint Pharmaceuticals	$7.61M	134.23	-$231.96M	-$3.50	N/A

Summary

Mirion Technologies beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Aehr Test Systems (NASDAQ:AEHR) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both measuring and control equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Aehr Test Systems had 8 more articles in the media than Eyepoint Pharmaceuticals. MarketBeat recorded 12 mentions for Aehr Test Systems and 4 mentions for Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals' average media sentiment score of 0.96 beat Aehr Test Systems' score of 0.83 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aehr Test Systems	5 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aehr Test Systems currently has a consensus target price of $117.50, suggesting a potential upside of 53.96%. Eyepoint Pharmaceuticals has a consensus target price of $43.75, suggesting a potential upside of 258.90%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Aehr Test Systems.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aehr Test Systems	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Aehr Test Systems has a beta of 3.17, indicating that its share price is 217% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

69.7% of Aehr Test Systems shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 6.8% of Aehr Test Systems shares are held by company insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aehr Test Systems has a net margin of -14.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Aehr Test Systems' return on equity of -4.48% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aehr Test Systems	-14.25%	-4.48%	-3.90%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Aehr Test Systems has higher revenue and earnings than Eyepoint Pharmaceuticals. Aehr Test Systems is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aehr Test Systems	$50M	48.01	-$7.13M	-$0.24	N/A
Eyepoint Pharmaceuticals	$7.61M	134.23	-$231.96M	-$3.50	N/A

Summary

Aehr Test Systems beats Eyepoint Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap measuring and control equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, profitability, dividends, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Eyepoint Pharmaceuticals had 3 more articles in the media than Alamar Biosciences. MarketBeat recorded 4 mentions for Eyepoint Pharmaceuticals and 1 mentions for Alamar Biosciences. Alamar Biosciences' average media sentiment score of 1.89 beat Eyepoint Pharmaceuticals' score of 0.96 indicating that Alamar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Alamar Biosciences	Very Positive
Eyepoint Pharmaceuticals	Positive

Alamar Biosciences has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Alamar Biosciences' return on equity of 0.00% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Alamar Biosciences currently has a consensus price target of $30.00, indicating a potential upside of 15.92%. Eyepoint Pharmaceuticals has a consensus price target of $43.75, indicating a potential upside of 258.90%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Alamar Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Alamar Biosciences is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$87.16M	20.58	-$120.60M	-$1.74	N/A
Eyepoint Pharmaceuticals	$7.61M	134.23	-$231.96M	-$3.50	N/A

Summary

Eyepoint Pharmaceuticals beats Alamar Biosciences on 9 of the 16 factors compared between the two stocks.

How does Eyepoint Pharmaceuticals compare to Allient?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Allient (NASDAQ:ALNT) are both small-cap measuring and control equipment companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 4 articles in the media. Allient's average media sentiment score of 1.25 beat Eyepoint Pharmaceuticals' score of 0.96 indicating that Allient is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Allient	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 61.6% of Allient shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 15.0% of Allient shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eyepoint Pharmaceuticals presently has a consensus price target of $43.75, indicating a potential upside of 258.90%. Allient has a consensus price target of $79.83, indicating a potential downside of 8.00%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Eyepoint Pharmaceuticals is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Allient has a net margin of 4.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Allient's return on equity of 12.47% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%
Allient	4.25%	12.47%	6.37%

Eyepoint Pharmaceuticals has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Allient has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

Allient has higher revenue and earnings than Eyepoint Pharmaceuticals. Eyepoint Pharmaceuticals is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$7.61M	134.23	-$231.96M	-$3.50	N/A
Allient	$554.48M	2.66	$22.03M	$1.43	60.69

Summary

Allient beats Eyepoint Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Eyepoint Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EYPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EYPT vs. The Competition

Export

Metric	Eyepoint Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.02B	$3.67B	$6.87B	$12.28B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	-3.48	21.29	27.11	23.71
Price / Sales	134.23	161.49	496.35	75.28
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	3.29	7.88	10.28	6.07
Net Income	-$231.96M	$23.86M	$3.60B	$331.99M
7 Day Performance	-8.35%	-3.82%	-1.27%	-0.63%
1 Month Performance	-11.09%	-2.61%	-0.37%	-2.00%
1 Year Performance	16.32%	32.79%	18.30%	13.62%

Eyepoint Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EYPT Eyepoint Pharmaceuticals	2.7231 of 5 stars	$12.19 -2.2%	$43.75 +258.9%	+16.2%	$1.02B	$7.61M	N/A	120	News Coverage
VNT Vontier	4.1682 of 5 stars	$30.41 +2.1%	$41.89 +37.8%	-21.0%	$4.28B	$3.08B	10.73	7,800
MIR Mirion Technologies	4.179 of 5 stars	$16.31 +3.4%	$26.38 +61.7%	-24.0%	$4.09B	$925.40M	163.26	3,281	Upcoming Earnings
AEHR Aehr Test Systems	4.2524 of 5 stars	$98.41 +27.2%	$117.50 +19.4%	+258.0%	$3.10B	$50M	N/A	90	Gap Up
ALMR Alamar Biosciences	3.3769 of 5 stars	$24.90 +4.1%	$30.00 +20.5%	N/A	$1.73B	$87.16M	N/A	222	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EYPT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. VNT, MIR, AEHR, ALMR, and ALNT

How does Eyepoint Pharmaceuticals compare to Vontier?

Summary

How does Eyepoint Pharmaceuticals compare to Mirion Technologies?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Summary

How does Eyepoint Pharmaceuticals compare to Allient?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eyepoint Pharmaceuticals (EYPT) Competitors

EYPT vs. VNT, MIR, AEHR, ALMR, and ALNT

How does Eyepoint Pharmaceuticals compare to Vontier?

Do analysts prefer VNT or EYPT?

Do institutionals & insiders have more ownership in VNT or EYPT?

Does the media prefer VNT or EYPT?

Is VNT or EYPT more profitable?

Which has more risk and volatility, VNT or EYPT?

Which has higher earnings & valuation, VNT or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Mirion Technologies?

Do analysts recommend MIR or EYPT?

Do insiders & institutionals believe in MIR or EYPT?

Does the media prefer MIR or EYPT?

Is MIR or EYPT more profitable?

Which has more volatility & risk, MIR or EYPT?

Which has better earnings & valuation, MIR or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Aehr Test Systems?

Does the media prefer AEHR or EYPT?

Do analysts recommend AEHR or EYPT?

Which has more volatility and risk, AEHR or EYPT?

Do institutionals & insiders have more ownership in AEHR or EYPT?

Is AEHR or EYPT more profitable?

Which has preferable earnings & valuation, AEHR or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Alamar Biosciences?

Does the media prefer ALMR or EYPT?

Is ALMR or EYPT more profitable?

Do analysts recommend ALMR or EYPT?

Do institutionals & insiders believe in ALMR or EYPT?

Which has stronger earnings and valuation, ALMR or EYPT?

Summary

How does Eyepoint Pharmaceuticals compare to Allient?

Does the media refer more to EYPT or ALNT?

Do insiders and institutionals have more ownership in EYPT or ALNT?

Do analysts recommend EYPT or ALNT?

Is EYPT or ALNT more profitable?

Which has more risk and volatility, EYPT or ALNT?

Which has stronger valuation & earnings, EYPT or ALNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EYPT vs. The Competition

Eyepoint Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools